gfp927z: No consensus about anything on the CTIX board that I've seen. Most of the posters there are expecting a partnership or additional financing through Aspire. I don't think most of them realize the costs involved with running a Phase 3 trial.
I'd agree with your guesstimate of $3 - $3.25 per share if the shelf were to be accessed today. Company may try to put it off as long as possible to keep the good news flowing and get the stock price back up above $4 before diluting.
My guess is that once a financing is finalized, there are a lot of people waiting on the sidelines that will be eager to become shareholders once the unknown becomes known, so I think the share price will recover quickly.
And, a partnership is still a possibility.... as you say, antibiotics have become a hot sector. Today's press release announcing the oral presentation at ECCMID hopefully helps build their credibility, in my opinion.
News 
Market Data 
Discover 
AI
